(VIANEWS) – The NYSE opens in less than hour and Zoetis‘s pre-market value is already 5.23% down.
Zoetis’s last close was $162.73, 19.41% under its 52-week high of $201.92.
The last session, NYSE ended with Zoetis (ZTS) dropping 0.29% to $162.73. NYSE slid 0.18% to $17,915.20, after two sequential sessions in a row of losses, on what was a somewhat bearish trend exchanging session.
About Zoetis
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.
Earnings Per Share
As for profitability, Zoetis has a trailing twelve months EPS of $5.07.
PE Ratio
Zoetis has a trailing twelve months price to earnings ratio of 32.1. Meaning, the purchaser of the share is investing $32.1 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 49.82%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 8.5%, now sitting on 8.54B for the twelve trailing months.
More news about Zoetis (ZTS).
